Introduction
============

Liver cancer is the third leading cause of cancer death worldwide[@B1]. Approximately 70% of HCC patients are diagnosed at an intermediate or advanced stage when curative treatments (including hepatic resection, ablation, and liver transplantation) are no longer feasible.

Transarterial chemoembolization (TACE) is widely recommended in clinical practice due to its high efficacy in patients with unresectable HCC[@B2]-[@B7]. TACE can significantly increase the 2-year survival rate from 27% to 63% compared with systemic therapy and supportive care in patients with unresectable HCC[@B8], [@B9]. There are increasing data to support that repeated TACE can significantly improve the tumor response rate and prolong overall survival (OS)[@B10], [@B11]. However, TACE is also associated with increased adverse effects and liver damage, potentially preventing a better prognosis[@B12]-[@B16]. Currently, the interval for repeated TACE varies among different medical centers, ranging from one to three months[@B17]-[@B20]. However, the efficacy and safety of various intervals of repeated TACE remain unknown.

We aimed to retrospectively compare the outcomes of TACE treatment with a long interval and a short interval between the first and second sessions in patients with unresectable HCC. A propensity score matching (PSM) analysis was used to reduce any potential confounding bias at baseline.

Methods
=======

Patients
--------

A total of 1443 patients with unresectable HCC received TACE as an initial treatment at the our Center between January 2007 and December 2014. The diagnosis of HCC was confirmed by radiological examination based on the European Association for the Study of Liver (EASL) criteria[@B21]. The interval between the first two TACE sessions was defined as the duration from the date of the first TACE procedure to the date of the second TACE procedure. We collected the following parameters as possible predictors of survival: demographics, risk factors of HCC and clinical data. Liver functional reserve was assessed using Child-Pugh grading and albumin-bilirubin (ALBI) grades.

The following inclusion criteria were used: (a) TACE as the primary treatment for HCC; (b) at least two TACE treatments received; (c) no intent for subsequent curative treatment including hepatic resection, ablation, or liver transplantation; (d) age between 18 and 75 years; (e) Child-Pugh A or B liver function; and (f) an Eastern Cooperative Oncology Group performance status of 0-2. The following exclusion criteria were used: (a) a repeated TACE interval of more than 90 days or less than 21 days; (b) the preoperative presence of severe conditions, such as cardiovascular disease or renal insufficiency; or (c) diagnosis of another malignancy. Patients with TACE intervals greater than the median interval were grouped into the short-interval group (SIG), and the remaining patients were grouped into the long-interval group (LIG).

The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, and the Ethics Committee of the Sun Yat-Sen University Cancer Center approved this study. Written informed consent was obtained before treatment.

TACE procedure
--------------

TACE was performed as previously described[@B22]. In all cases, the TACE procedure was performed under local anesthesia by a hepatologist with more than 10 years of experience in interventional therapy for HCC. First, visceral angiography was routinely performed to assess tumor vascularity, vascular anatomy and portal vein patency using a 5-F catheter. We excluded the existence of an arteriovenous shunt based on visceral angiography. Then, depending on the tumor distribution, tumor size and arterial supply to the tumor, the tip of the catheter was advanced into the right or left hepatic artery to perform selective arterial embolization. A 2.9-F microcatheter (Terumo, Tokyo, Japan) was used if the 5-F catheter could not advance into the tumor-feeding artery. Next, 300 mg of carboplatin (Bristol Myers Squibb, New York, NY) was used for hepatic artery infusion chemotherapy. Then, a mixture of 50 mg of epirubicin (Pharmorubicin; Pfizer, Wuxi, China), 8 mg of mitomycin C (Zhejiang Hisun Pharmaceutical, Taizhou, China) or 500 mg of 5-FU, and 2-5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay Sous-Bois, France) was injected into the tumor distribution for chemolipiodolization. Pure lipiodol was injected into the arterial supply of the tumor until a substantial reduction in flow to the tumor distribution was achieved. Finally, X-ray imaging of the chest and abdomen was performed to verify the distribution of lipiodol and to exclude ectopic embolization.

Follow-up and repeat TACE
-------------------------

Enhanced computed tomography (CT) or magnetic resonance imaging (MRI) was performed one week before and four to six weeks after TACE-2 by experienced radiologists and hepatologists for an assessment of the radiologic tumor response according to the Modified Response Evaluation Criteria in Solid Tumors criterion (mRECIST)[@B23]. Detailed blood tests and chest radiography were performed during follow-up visits. The decision for repeated TACE was made by a multidisciplinary team of experts including a radiologist, interventional radiologists, oncologists and surgeons. Generally, repeated TACE treatment was performed at 4- to 8-week intervals until the following end points were reached: (1) tumor progression; (2) deterioration of liver function; (3) Eastern Cooperative Group score \> 2; or (4) patients\' refusal to TACE.

TACE-related adverse events were evaluated within four weeks after treatment. Hematotoxicity was evaluated and graded according to the common terminology criteria for adverse events (CTCAE) version 4.0[@B24], and the intensity was characterized as mild, moderate, severe, life-threatening, or fatal. Hyperpyrexia was defined as the presentation of a fever over 39 degrees within one week after TACE-2.

Statistical analysis
--------------------

We performed PSM analysis to reduce the bias of variables associated with treatment selection and outcome prediction. Variables identified by Logistic regression and were considered as important based on clinical practice were introduced to generate a propensity score. A one-to-one nearest neighbor matching algorithm with a caliper of 0.2 and without replacement was used.

We applied an independent sample t-test and the Mann-Whitney U-test to analyze continuous variables. The chi-square test and the Kruskal-Wallis test were used to analyze binary and ordinal categorical variables, respectively. The OS was calculated as the interval between the date of initial TACE and death or the last follow-up. We used the Kaplan-Meier method and the log-rank test to estimate and compare OS. Median survival times and their 95% confidence intervals (CI) were reported. A univariate analysis was performed to identify the factors that predicted survival. All variables with P \< 0.05 based on the univariate analysis were included in a multivariate analysis. The multivariate analysis was performed with the Cox proportional hazards model. All statistical analyses were performed by SPSS (IBM SPSS Statistics for WINDOWS, Version 20.0, IBM Corp., Armonk, NY, USA) and PSM for SPSS, Version 3.02 (Felix Thoemmes, Cornell University/University of Tübingen, and Wang Liao, Cornell University). The P-values are the results of two-sided tests. A level of 0.05 was defined for statistically significant differences.

Results
=======

Study population
----------------

A total of 1443 HCC patients initially treated with TACE between January 2007 and December 2014 at the Sun Yat-Sen University Cancer Center were included in the study. Of these, 869 individuals were excluded for the following reasons: only one session of TACE (n = 203), subsequent hepatic resection (n = 223), ablation (n = 188), or liver transplantation (n = 2), an interval of more than 90 days (n = 171 patients) or less than 21 days (n = 61) between the first two TACE sessions, a history of other malignant tumors (n = 5) and lack of follow-up (n = 16). Ultimately, 574 patients were enrolled (Figure [1](#F1){ref-type="fig"}). Among them, the numbers of patients who underwent 2, 3, 4, or 5 or more sessions of TACE were 378 (65.9%), 123 (21.4%), 47 (8.2%), and 26 (4.5%), respectively. The median interval between the first two TACE sessions was 48 days.

The clinical characteristics observed before and after patient matching are shown in Table [1](#T1){ref-type="table"}, Table [2](#T2){ref-type="table"}. Patients with intervals shorter than the median interval were assigned to the SIG (n = 315), and the remaining patients were assigned to the LIG (n = 259). The numbers of patients with ALBI grades of -1, -2, and -3 prior to initial TACE were 170 (54.0%), 142 (45.1%), and 3 (1.0%), respectively, for SIG patients and 142 (54.8%), 115 (44.4%), and 2 (0.8%), respectively, for LIG patients. The distributions of ALB were similar in the SIG and LIG before and after matching (Table [1](#T1){ref-type="table"}, 2; P = 0.824, 0.960).

The SIG had more male patients (94.0% vs. 89.6%, P = 0.038), larger tumor sizes (cm, 10.4 vs. 9.4, P = 0.006), higher γ-glutamyl transferase levels (U/L, median level: 190.6 vs. 151.6, P = 0.003), and higher white blood cell counts (10^12^/L, median level: 7.00 vs. 6.60, P = 0.034) than the LIG.

Overall survival
----------------

The mean length of follow-up was 11.0 months (range, 1.0 - 124.0 months). The OS was greater in the LIG than in the SIG (P = 0.003; hazard ratio \[HR\], 0.752; 95% CI, 0.622 to 0.908; Figure [2](#F2){ref-type="fig"}). The median survivals of the SIG and LIG were 8.7 and 12.1 months (P = 0.003), respectively. The 1-, 2-, and 3-year survival rates were 36.3%, 17.6%, and 10.3%, respectively, in the SIG and 50.7%, 20.7%, and 11.4% in the LIG, respectively.

After PSM
---------

### Baseline

We used PSM analysis to reduce the bias of covariances associated with patient selection between the SIG and LIG. The variables included in the analysis were gender, white blood cell count, gamma-glutamyl transpeptidase level, AFP, tumor size, and platelet count. In total, 238 patients in the SIG and 238 patients in the LIG were matched for further analyses. Any baseline characteristics that were significantly different between the patient groups were well-balanced after matching (Table [2](#T2){ref-type="table"}).

The baseline biochemical results prior to TACE-2 were comparable between the SIG and the LIG. The GGT level was significantly higher (U/L, median: 201 vs. 190) in the SIG. The SIG had poorer liver function prior to TACE-2 than the LIG, a lower ALB level (g/L, 37.38 ± 4.34 vs. 38.82 ± 5.78, P = 0.013), and more ALBI grade 2 and 3 patients (64.3% vs. 54.6%, P = 0.027; Supplementary Table [1](#SM0){ref-type="supplementary-material"}).

The radiologic tumor responses after TACE-1 and TACE-2 are given in Supplementary Table [2](#SM0){ref-type="supplementary-material"}. The SIG and LIG showed similar complete response (5.0% vs. 7.6%), partial response (37.8% vs. 37.0%), stable disease (48.3% vs. 46.6%), and progressive disease (8.8% vs. 8.8%) statuses after TACE-1 (P = 0.603). Moreover, no significant difference in tumor response after TACE-2 was observed between the SIG and LIG (P = 0.852).

Adverse events after TACE-2
---------------------------

No statistically significant difference between the SIG and LIG was found for the overall number of patients who reported adverse events (Table [3](#T3){ref-type="table"}; 29.4% vs. 33.6%, P = 0.324). The most common treatment-related nonhematologic adverse events are listed in Table [3](#T3){ref-type="table"}. The complications included hyperpyrexia (n = 42), vomiting (n = 20), myelosuppression (n = 1), hypohepatia (n = 2), cholangitis (n = 1), pulmonary infection (n = 2), hepatapostema (n = 1) and gastrointestinal bleeding (n = 1) in the SIG. The complications included hyperpyrexia (n = 55), vomiting (n = 21), myelosuppression (n = 2) and hypohepatia (n = 2) in the LIG.

Overall survival and prognostic factors
---------------------------------------

In matched patients, the LIG had a significantly better OS than the SIG (P \< 0.001; HR, 0.623; 95% CI, 0.504 to 0.771; Figure [3](#F3){ref-type="fig"}). The median OS rates of the SIG and LIG were 9.1 months and 14.2 months, respectively. The 1-, 2-, and 3-year survival rates were 37.5%, 17.1% and 9.9%, respectively, in the SIG and 50.1%, 19.3% and 11.6% in the LIG, respectively.

Univariate analyses showed that a short interval (P = 0.011), Child-Pugh B grade (P = 0.016), AFP \> 400 ng/ml (P = 0.027), PVTT presence (P = 0.002), radiologic tumor response absent (P \< 0.001) and tumor size \> 10 cm (P = 0.002) were significantly associated with a poor OS. Cox analysis identified a short interval (HR = 1.399; 95% CI: 1.135 - 1.725; P = 0.002), radiologic tumor response absent (HR = 0.636; 95% CI: 0.515 - 0.786; P \< 0.001), and tumor size \> 10 cm (HR = 1.366; 95% CI: 1.105 - 1.675; P = 0.004) as independent adverse prognostic factors for OS (Table [4](#T4){ref-type="table"}).

Outcomes within Barcelona Clinic liver cancer (BCLC) subgroups
--------------------------------------------------------------

The median survivals of the SIG and LIG were 11.8 months and 12.8 months (HR = 1.044; 95% CI: 0.661 - 1.648; P = 0.853) for BCLC stage A and 10.9 months and 12.4 months for BCLC stage B (HR = 0.809; 95% CI: 0.593 - 1.103; P = 0.180), respectively. However, in the BCLC stage C group, the LIG (n = 76) had a better OS than the SIG (n = 82), and the median survivals in the SIG and LIG were 5.8 months and 10.2 months, respectively (HR = 0.525; 95% CI: 0.359 - 0.767; P \< 0.001). The 1-, 2-, and 3-year survival rates were 18.6%, 12.8%, and 6.4% in the SIG and 44.3%, 15.2%, and 13.3% in the LIG, respectively (Figure [3](#F3){ref-type="fig"}).

Discussion
==========

Although TACE is the most widely used primary treatment for unresectable HCC, there is no standard TACE treatment schedule for patients with unresectable HCC and definitive data suggesting a superior strategy in terms of efficacy are lacking. In the current study, we compared outcomes between long- and short-interval TACE in patients with unresectable HCC. The OS was greater in the LIG than in the SIG before matching. After matching, we found that the LIG had a better OS than the SIG and that a short interval was an independent adverse prognostic factor for OS. Further analyses showed a significant difference in OS between the LIG and SIG among BCLC-C patients compared to BCLC-A and BCLC-B patients. Kim et al. reported that the TACE interval did not affect the survival outcomes of patients with Child-Pugh class A, but it did adversely affect survival in patients with Child-Pugh class B[@B20]. The difference between their study and ours may be due to the heterogeneity of the patient cohorts. On one hand, our study had more BCLC stage C patients who suffered from portal vein invasion (33.2%, 158/476) than their study with a rate of 10.6% (22/208). The significant difference in OS between the SIG and LIG in BCLC stage C patients may affect the results of all patients. On the other hand, the considerable number of cases in our study provides more convincing results by limiting any bias or confounding factors. Although our findings of this study cannot give definite TACE treatment schedule for unresectable HCC patients, our research has a positive significance to propose feasible suggestions for clinical practice. We can give difference interval of TACEs based on BCLC stages to increase the efficacy of treatment.

Most HCC patients who are candidates for TACE suffer from HBV infection, cirrhosis or major portal vein invasion, which are associated with a poor hepatic reserve[@B25]. These patients may experience more serious hepatic function damage after repeated TACE[@B26], [@B27]. Thus, a sufficient amount of time is necessary for recovery to normal hepatic function. This expectation was supported by a higher proportion of ALBI grade 1 patients in the LIG compared with the SIG (45.4% vs. 35.7%, P = 0.027). Previous studies have shown that the ALBI grade is a prognostic factor for OS in patients with HCC[@B28], [@B29]. Therefore, we believe that a better OS is related to better liver function recovery after initial TACE as a result of a longer interval before the second session. Liver function in BCLC stage C patients who present portal vein invasion may be severely damaged by repeated TACE due to the original blood supply shortage. Therefore, these patients require more time to recover than BCLC-A and BCLC-B patients without PVTT. When planning for the next session TACE in BCLC-C patients, one should be cautious and extend the interval between sessions.

Additionally, the interval for repeated TACE in clinical practice ranges from one to three months or even longer in different medical centers. In China, the radiologic tumor response was generally evaluated within 3 to 6 weeks after initial TACE treatment. Therefore, most patients who are eligible for repeated TACE receive the next treatment session within 3 months. For patients with interval less than 21 days, the second TACE is a savage treatment for the failure of the first TACE treatment. A interval of repeated TACEs over 90 days suggests a poor compliance of treatment and follow-up. Therefore, we only included patients with TACE intervals of 21 to 90 days to avoid patient selection bias. The median TACE interval in this study was 48 days, which is consistent with results from other studies[@B18], [@B30]. We used 48 days as the cutoff to determine the long- and short-interval groups to adequately reflect real-life clinical practice.

Blocking the blood supply to a tumor by embolization and attacking tumor cells via cytotoxic chemotherapy contribute to the antitumoral effect of TACE[@B31]. Accordingly, the complications of TACE include postembolization syndrome, such as fever and abdominal pain, and side effects from chemotherapy, such as nausea, vomiting, deteriorated liver function and hematotoxicity[@B16], [@B32]. The side effects of TACE were frequent but mild and most cases of postembolization syndrome resolve within one month[@B33]. In this study, the median interval between the first two TACE sessions was 48 days; thus, most patients had recovered from the post-treatment side effects of TACE. Therefore, no differences in complications were found between the SIG and LIG.

Our study has some limitations. First, the potential bias of patient allocation cannot be completely avoided since this is a retrospective study. Second, we limited the interval range from 21 days to 90 days; the issue of whether longer or shorter intervals show similar findings remains uncertain. Such factors limit the generalizability of our conclusions and need to be resolved in the near future. Third, this is a single-center study; hence, these findings may not be consistent with results for other centers and geographic regions. To obtain more generalizable results, an independent external validation database may be necessary.

Conclusions
===========

A long interval between the first two sessions of TACE resulted in a better OS than a short interval in BCLC-C stage HCC patients.
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###### 

Characteristics of all patients before first session TACE

  -------------------------------------------------------------------------------------------------
                                                 All patients               p              
  ------------------- -------------------------- -------------------------- -------------- --------
  Gender ( M/F )      296/19                     232/27                     0.038          

  Age, year           51 (25 - 82)               53 (18 - 80)               0.146          

  Hepatitis B ( % )   280 (88.89%)               220 (84.94%)               0.160          

  Hepatitis C ( % )   3 (0.95%)                  8 (3.09%)                  0.073          

  WBC, 10^9^/L        7.00 (2.70 - 17.60)        6.60 (2.16 - 24.60)        0.034          

  RBC, 10^9^/L        4.64 (2.76 - 7.35)         4.61 (2.50 - 7.34)         0.542          

  HB, g/L             138.00 (83.70 - 198.00)    137.00 (65.40 - 185.00)    0.146          

  PLT, 10^9^/L        201.4 (31.00 - 749.70)     185.00 (12.10 - 604.00)    0.090          

  ALT, U/L            47.10 (8.70 - 322.70)      46.40 (9.10 - 455.00)      0.533          

  AST, U/L            62.40 (17.00 - 736.60)     60.50 (9.70 - 1332.50)     0.285          

  GGT, U/L            190.60 (24.50 - 2480.00)   151.60 (20.70 - 1524.10)   0.003          

  ALB, g/L            40.20 (26.70 - 73.21)      40.00 (22.30 - 54.00)      0.994          

  TBIL, μmol/L        15.40 (3.60 - 225.00)      14.70 (5.60 - 616.30)      0.180          

  Creatine, μmol/L    73.16 (36.5 - 217.40)      73.30 (3.35 - 112.90)      0.960          

  PT, sec             12.20 (8.70 - 23.00)       12.30 (8.70 - 20.30)       0.297          

  CRP, mg/L           11.83 (0.25 - 208.18)      10.65 (0.21 - 241.30)      0.078          

  INR                 1.06 (0.76 - 2.05)         1.06 (0.76 - 1.61)         0.390          

  AFP, ng/ml          \< 200                     107 (33.97%)               104 (40.15%)   

                      200 - 400                  13 (4.13%)                 11 (4.25%)     

                      \> 400                     195 (61.90%)               144 (55.60%)   0.119

  Tumor-Size, cm      10.4 (1.0 - 19.8)          9.4 (1.0 - 25.0)           0.006          

  Tumor number        Solitary                   121 (38.41%)               83 (32.05%)    

                      Multifocal                 194 (61.59%)               176 (67.95%)   0.113

  PVTT                Absent                     204 (64.76%)               181 (69.88%)   

                      Present                    111 (35.24%)               78 (30.12%)    0.194

  Times of TACE       2                          202 (64.13%)               176 (67.95%)   

                      3                          69 (21.90%)                54 (20.85%)    

                      \>= 4                      44 (13.97%)                29 (11.20%)    0.291

  Child-Pugh stage    A                          295 (93.64%)               241 (93.05%)   

                      B                          20 (6.36%)                 18 (6.95%)     0.773

  BCLC stage          A                          75 (23.80%)                59 (22.78%)    

                      B                          129 (40.96%)               121 (46.72%)   

                      C                          111 (35.24%)               79 (30.50%)    0.520

  ABIL grade          1                          170 (53.97%)               142 (54.83%)   

                      2                          142 (45.08%)               115 (44.40%)   

  Iodized oil, ml     3                          3 (0.95%)\                 2 (0.77%)\     0.824\
                                                 19 ± 7.5                   18.0 ± 7.2     0.173
  -------------------------------------------------------------------------------------------------

Abbreviations: WBC, white blood cell; RBC, red blood cell; HB, hemoglobin; PLT, platelet; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; ALB, albumin; TBIL, total bilirubin; PT, prothrombin time; CRP, C-reactive protein; INR, international normalized ratio; AFP, alpha fetoprotein; PVTT, portal vein tumor thrombus; TACE, transcatheter arterial chemoembolization; BCLC, Barcelona Clinical Liver Cancer; ABIL, Albumin-Bilirubin.

###### 

Characteristics of after matching patients before first session TACE

  Variables                                      Matched patients           p              
  ------------------- -------------------------- -------------------------- -------------- -------
  Gender ( M/F )      225/13                     213/25                     0.062          
  Age, year           50 (25 - 82)               53 (18 - 80)               0.283          
  Hepatitis B ( % )   210 (88.23%)               201 (84.45%)               0.286          
  Hepatitis C ( % )   3 (1.26%)                  8 (3.436%)                 0.221          
  WBC, 10^9^/L        6.80 (2.70 - 17.60)        6.67 (2.80 - 24.60)        0.650          
  RBC, 10^9^/L        4.64 (2.76 - 6.85)         4.64 (2.68 - 7.34)         0.841          
  HB, g/L             138.30 (83.70 - 192.00)    137.00 (65.40 - 185.00)    0.328          
  PLT, 10^9^/L        199.40 (31.00 - 749.70)    188.85 (12.10 - 604.00)    0.598          
  ALT, U/L            43.70 (8.70 - 322.70)      46.4 (9.1 - 455.00)        0.805          
  AST, U/L            60.00 (23.10 - 422.10)     61.10 (9.70 - 1332.50)     0.758          
  GGT, U/L            178.15 (24.50 - 1433.20)   159.25 (21.80 - 1017.90)   0.563          
  ALB, g/L            40.40 (26.70 - 73.21)      40.10 (22.30 - 54.00)      0.984          
  TBIL, μmol/L        15.05 (3.60 - 225.00)      14.50 (5.60 - 616.30)      0.287          
  Creatine, μmol/L    73.00 (43.38 - 217.40)     73.33 (3.35 - 112.90)      0.724          
  PT, sec             12.20 (9.90 - 19.50)       12.25 (8.70 - 20.30)       0.674          
  CRP, mg/L           11.73 (0.25 - 208.18)      11.7 (0.46 - 241.3)        0.682          
  INR                 1.06 (0.84 - 2.05)         1.06 (0.76 - 13.20)        0.758          
  AFP, ng/ml          \< 200                     86 (36.14%)                96 (40.34%)    
                      200 - 400                  8 (3.36%)                  11 (4.62%)     
                      \> 400                     144 (60.50%)               131 (55.04%)   0.262
  Tumor-Size, cm      10.0 (1.0 - 19.1)          9.7 (1.0 - 20)             0.940          
  Tumor number        Solitary                   86 (36.13%)                82 (34.45%)    
                      Multifocal                 152 (63.87%)               156 (65.55%)   0.701
  PVTT                Absent                     156 (65.55%)               163 (68.49%)   
                      Present                    82 (34.45%)                75 (31.51%)    0.495
  Times of TACE       2                          164 (68.90%)               146 (61.35%)   
                      3                          49 (20.59%)                52 (21.85%)    
                      \>= 4                      25 (10.51%)                40 (16.80%)    0.051
  Iodized oil, ml                                18.9 ± 7.4                 18.5 ± 7.1     0.625
  Child-Pugh stage    A                          221 (92.86%)               223 (93.70%)   
                      B                          17 (7.14%)                 15 (6.30%)     0.714
  BCLC stage          A                          48 (20.17%)                55 (23.11%)    
                      B                          108 (45.38%)               107 (44.96%)   
                      C                          82 (34.45%)                76 (31.93%)    0.423
  ABIL grade          1                          133 (55.88%)               132 (55.46%)   
                      2                          102 (42.86%)               104 (43.70%)   
                      3                          3 (1.26%)                  2 (0.84%)      0.960

Values are presented as the median(Range) or n (%)

Abbreviations: WBC, white blood cell; RBC, red blood cell; HB, hemoglobin; PLT, platelet; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; ALB, albumin; TBIL, total bilirubin; PT, prothrombin time; CRP, C-reactive protein; INR, international normalized ratio; AFP, alpha fetoprotein; PVTT, portal vein tumor thrombus; TACE, transcatheter arterial chemoembolization; BCLC, Barcelona Clinical Liver Cancer; ABIL, Albumin-Bilirubin.

###### 

Hematotoxicity and adverse event after TACE-2

  Hematotoxicity              Grade      SIG (n = 238)   LIG (n = 238)   P
  --------------------------- ---------- --------------- --------------- ----------
  Leukopenia                  1          14              21              
                              2          4               9               
                              3          0               2               0.368^‡^
  Anemia                      1          67              80              
                              2          33              36              
                              3+4        5               10              0.960
  Thrombocytopenia            1          29              31              
                              2          35              23              
                              3+4        10              11              0.065
  Hypoalbuminemia             1          79              86              
                              2          19              20              0.925
  TBIL increased              1          101             0               
                              2          78              4               0.073^‡^
  Adverse events                         SIG (n = 238)   LIG (n = 238)   P
  Hyperpyrexia                           42 (17.6%)      55 (23.1%)      0.139
  Vomit                                  20 (8.4%)       21 (8.8%)       0.870
  Myelosuppression                       1 (0.4%)        2 (0.8%)        1.000^‡^
  Hypohepatia                            2 (0.8%)        2 (0.8%)        1.000^‡^
  Cholangitis                            1 (0.4%)        0               1.000^†^
  Pulmonary infection                    2 (0.8%)        0               1.000^‡^
  Gastrointestinal bleeding   1 (0.4%)   0               1.000           
  Hepatapostema                          1 (0.4%)        0               1.000^†^
  Total                                  70 (29.4%)      80 (33.6%)      0.324

\* The grade of adverse event were evalued according to the common terminology criteria for adverse events (CTCAE) version 4.0

†: Fisher exact test.

‡: χ^2^ test with a continuity correction.

TACE-2, the second session transarterial chemoembolization

SIG, short-interval group; LIG, long-interval group

###### 

Univariate and multivariate analysis for OS in matched patients

  Variable                     group      Univariate analysis   Multivariate analysis                                                        
  ---------------------------- ---------- --------------------- ----------------------- ----------------- ------- --------------- ---------- --
  Sex                          Male       438                   10.30                   9.113 - 11.487                                       
                               Female     38                    10.30                   5.118 - 15.482    0.977                              
  Age (years)                  \<65       417                   9.90                    8.904 - 10.896                                       
                               \>=65      59                    14.20                   11.934 - 16.466   0.165                              
  Child-Pugh stage             A          444                   10.50                   9.307 - 11.693                                       
  B                            32         7.00                  2.605 - 11.395          0.016                                                
  ALBI grade                   1          193                   11.80                   10.083 - 13.517                                      
                               2          277                   9.10                    7.792 - 10.408                                       
                               3          6                     8.80                    1.599 - 16.001    0.037                              
  Alpha-Fetoprotein            \<= 200    182                   12.10                   10.149 - 14.051                                      
  200 - 400                    19         17.30                 1.00 - 35.024                                                                
  \> 400                       275        9.30                  8.421 - 10.179          0.027                                                
  Tumor number                 Unifocal   168                   9.80                    7.905 - 11.695                                       
  Multifocal                   308        10.70                 9.037 - 12.363          0.622                                                
  Portal vein tumor thrombus   Present    319                   11.90                   10.550 - 13.250                                      
  Absent                       157        8.30                  7.331 - 9.269           0.002                                                
  Albumin, g/L                 \<35       73                    9.30                    7.915 - 10.685                                       
                               \>=35      403                   10.50                   9.270 - 11.730    0.364                              
  Total bilirubin, μmol/L      \>17       314                   11.30                   10.088 - 12.512                                      
  \<=17                        162        9.00                  7.946 - 10.054          0.208                                                
  Prothrombin time, sec.       \>13.5     412                   10.30                   8.999 - 11.601                                       
  \<=13.5                      64         10.20                 5.813 - 14.587          0.755                                                
  TACE interval                \<=48      238                   8.90                    7.779 - 10.021                                       
  \>48                         238        12.10                 10.445 - 13.755         0.011             1.399   1.135 - 1.725   0.002      
  Radiologic tumor response    Present    271                   13.00                   11.438 - 14.562                                      
  Absent                       205        8.30                  7.370 - 9.230           \<0.001           0.636   0.515 - 0.786   \< 0.001   
  Tumor size, cm               \<=10      251                   12.40                   10.714 - 14.086                                      
  \>10                         225        8.90                  7.960 - 9.835           0.002             1.366   1.105 - 1.675   0.004      

OS: Overall survival; ALBI: Albumin-Bilirubin grade; TACE: transarterial chemoembolization; HR: hazard ratio; CI: Confidence Interval.

[^1]: \* These authors contributed equally to this work.
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